IRIS Institutional Research Information System - OPENBS Open Archive UniBS

TORTI, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.525
AS - Asia 5.242
EU - Europa 4.105
SA - Sud America 1.113
AF - Africa 69
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 10
Totale 22.083
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.398
CN - Cina 1.917
SG - Singapore 1.720
UA - Ucraina 1.419
BR - Brasile 950
DE - Germania 802
HK - Hong Kong 732
IT - Italia 434
FI - Finlandia 371
GB - Regno Unito 294
VN - Vietnam 250
RU - Federazione Russa 239
IE - Irlanda 225
TR - Turchia 211
IN - India 159
FR - Francia 113
AR - Argentina 64
CA - Canada 64
BD - Bangladesh 56
MX - Messico 39
EC - Ecuador 38
IQ - Iraq 38
SE - Svezia 38
BE - Belgio 27
AT - Austria 23
ZA - Sudafrica 23
PL - Polonia 22
JP - Giappone 20
NL - Olanda 20
AU - Australia 17
ID - Indonesia 16
IR - Iran 16
PK - Pakistan 15
VE - Venezuela 15
CZ - Repubblica Ceca 14
ES - Italia 13
LT - Lituania 12
CO - Colombia 11
KE - Kenya 11
PY - Paraguay 11
SA - Arabia Saudita 11
UZ - Uzbekistan 11
EG - Egitto 10
EU - Europa 9
IL - Israele 9
AZ - Azerbaigian 8
CL - Cile 7
PT - Portogallo 7
TN - Tunisia 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
HN - Honduras 6
JO - Giordania 6
KZ - Kazakistan 6
MA - Marocco 6
PE - Perù 6
MY - Malesia 5
NP - Nepal 5
OM - Oman 5
DZ - Algeria 4
HU - Ungheria 4
JM - Giamaica 4
MU - Mauritius 4
BG - Bulgaria 3
DO - Repubblica Dominicana 3
LV - Lettonia 3
MD - Moldavia 3
PA - Panama 3
PH - Filippine 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
BO - Bolivia 2
BY - Bielorussia 2
CH - Svizzera 2
GR - Grecia 2
GY - Guiana 2
HR - Croazia 2
KG - Kirghizistan 2
KR - Corea 2
MS - Montserrat 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
CY - Cipro 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MN - Mongolia 1
NO - Norvegia 1
PS - Palestinian Territory 1
Totale 22.076
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.410
Fairfield 1.409
Jacksonville 1.031
Ashburn 891
Houston 879
Singapore 856
Hong Kong 730
Ann Arbor 704
Cambridge 615
Seattle 612
Wilmington 568
Chandler 431
Princeton 411
Nanjing 393
Beijing 347
Dublin 224
Istanbul 174
New York 162
Los Angeles 161
Nanchang 147
Helsinki 143
The Dalles 112
Moscow 107
Des Moines 104
Ho Chi Minh City 99
San Diego 96
Hebei 92
Shenyang 90
Changsha 86
Buffalo 83
São Paulo 76
Jinan 67
Tianjin 65
Lancaster 64
San Francisco 60
Jiaxing 58
Munich 58
Shanghai 58
Milan 54
Redondo Beach 52
Dearborn 51
Hanoi 49
Kunming 39
Dallas 37
Hangzhou 37
Chicago 35
Verona 34
Brescia 31
London 28
Toronto 28
Brussels 27
Belo Horizonte 26
Rio de Janeiro 26
Santa Clara 21
Turku 21
Montreal 19
Ningbo 19
Nuremberg 19
Warsaw 19
Zhengzhou 19
Tokyo 18
Washington 18
Boardman 17
Guangzhou 17
Lanzhou 17
Porto Alegre 17
Ardabil 16
Atlanta 16
Brasília 16
Campinas 16
Brooklyn 15
Curitiba 15
Frankfurt am Main 15
Quito 15
Changchun 14
Mexico City 14
Kocaeli 13
Johannesburg 12
Norwalk 12
Ribeirão Preto 12
Salvador 12
Dhaka 11
Taizhou 11
Tashkent 11
Buenos Aires 10
Guayaquil 10
Haikou 10
Nairobi 10
Orange 10
Augusta 9
Brno 9
Da Nang 9
Poplar 9
Taiyuan 9
Baku 8
Biên Hòa 8
Boston 8
Erbil 8
Melbourne 8
Mumbai 8
Totale 14.857
Salva come PNG Salva come JPEG
Nome #
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. 281
The Disagreement Among Methods to Evaluate Glomerular Filtration Rate in HIV-Infected Patients Naive to Antiretroviral Therapy. 219
The evolving burden of HIV infection compared with other chronic diseases in northern Italy 198
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection 191
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 189
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy 176
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy 167
HIV-associated asymmetric lipodystrophy syndrome 163
Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons 161
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting 159
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 159
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. 158
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 157
Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report. 156
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy 156
Key Questions in antiretroviral therapy: Italian Consensus Workshop (2005) 155
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. 153
Virological effectiveness and CD4+ T-cell increase over early andlate courses in HIV infected patients on antiretroviral therapy: focus on HCV andanchor class received 152
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. 151
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study. 148
Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications. 148
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 147
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. 146
Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide 145
Bcl-2 expression is moderately correlated with long-term variability of CD4+ T-cell increase under successful highly active antiretroviral therapy 145
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations 144
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. 144
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 142
HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir containing regimens 141
Impact of detectable human cytomegalovirus DNAemia on viro-immunologicaleffectiveness of HAART in HIV-infected patients naive to antiretroviral therapy 139
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target? 138
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. 137
Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone. 136
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study 136
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 136
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy 135
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction 135
Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients 135
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. 134
All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration  134
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI 132
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the “COPA” pilot randomized trial 129
Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART) 129
Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis 128
Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). 128
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. 127
The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool 126
Towards HCV extinction with modern HCV treatment? “Yes we can!” 126
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48 week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial 125
Polymorphic immune restoration syndrome after effective HAART 125
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 124
Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response 123
CD4+ T cell evolution and predictors of its trend before and aftertenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 123
A king in the CASTLE? Optimum initial HIV protease inhibitor. 122
Potential role of SEN virus on liver enzyme abnormalities in patients positive for hepatitis C virus with or without HIV infection. 122
Risk factors for myocardial infarction in HIV positive patients 122
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 121
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART 121
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts 121
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 121
Analisi estensiva di sequenza dei geni della trascrittasi inversa e della proteasi di HIV-1 in una coorte clinica di pazienti HIV positivi NAIVE per la terapia antiretrovirale. 120
Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. 120
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies 119
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study 119
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 118
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort 118
The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions 118
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study 118
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study 118
Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study. 116
First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006). 116
Long-term immunological benefit in patients with discordant responses to therapy depends on both level of viremia and duration of rebound 116
HIV/HTLV co-infection: frequency and epidemiological characteristics among patients admitted to an Italian hospital 115
The use of ultrasonography, transient elestography, APRI and FIB-4 to measure liver steatosis and fibrosis in HIV-positive patients not co-infected with hepatitis viruses with hypertransaminasemia of unknown origin on HAART 115
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads 115
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 114
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis 114
Genetic polymorphisms differently influencing the emergence of atrophy and fataccumulation in HIV-related lipodystrophy 114
Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes 113
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals 112
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years 112
Risk of triple-class virological failure in children with HIV: a retrospective cohort study 111
Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. 110
Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. 110
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal 110
Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch 110
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 109
The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients 109
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures 109
Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors 108
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 108
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. 108
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations. 108
The Impact of Gender and Anchor Drugs on TDF Renal Toxicity 108
Diagnosi sierologica di infezioni da HIV 2: confronto tra Western Blot NEW LAW Blot II e PEPTI-LAV 1-2 107
Screening and Management of HIV-2-Infected Individuals in Northern Italy. 107
Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients 107
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. 107
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE) 107
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy 107
Totale 13.241
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.248
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.248
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.900 0 0 0 0 0 348 135 394 421 251 265 86
2021/20221.477 76 275 7 89 5 87 61 98 69 195 141 374
2022/20231.374 225 18 11 83 131 416 0 129 228 15 44 74
2023/20241.164 74 24 67 114 46 172 35 32 372 14 15 199
2024/20253.076 28 10 12 339 440 247 319 101 290 263 637 390
2025/20263.406 576 854 398 880 632 66 0 0 0 0 0 0
Totale 22.238